NORTH BILLERICA, Mass. -- (BUSINESS WIRE) -- Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced the appointment of Cesare Orlandi, M.D., as the Company’s new Chief Medical Officer. Dr. Orlandi brings to the Company more than 20 years of diverse pharmaceutical industry experience with a proven track record of directing successful drug development programs, providing leadership in product pipeline portfolio management and overseeing interactions with regulatory agencies. Additionally, Dr. Orlandi has extensive experience with global development leadership, including emerging markets.
In his role as Chief Medical Officer, Dr. Orlandi will be responsible for leading Clinical Development, Medical Affairs, Pharmacovigilence and Regulatory Affairs for the Company, including its Phase 3 clinical trial program for flurpiridaz F 18. He will report directly to Jeff Bailey, President and CEO, Lantheus Medical Imaging.
“Cesare’s versatile and cross-functional experience with leading clinical programs and product life cycle management will bring significant benefits to our Company,” said Bailey. “His proven success with drug development, combined with his cardiovascular imaging expertise and extensive industry knowledge, make him ideal for advancing our clinical development strategy and championing our ongoing commitment to patient safety."
Dr. Orlandi most recently served as Senior Vice President and Chief Medical Officer of TransTech Pharma, Inc., a clinical stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs, where he led drug development from Phase 1 through Phase 3 trials for the company’s pipeline programs. Prior to joining TransTech in January 2012, Dr. Orlandi served as the Senior Vice President and Chief Medical Officer of Cardiokine, Inc., a specialty pharmaceutical company focused on developing hospital products for cardiovascular indications, completing the late stage development of lixivaptan, a Phase 3 program in 20 countries and more than 500 sites worldwide. Earlier in his career, he worked with Otsuka Pharmaceuticals as Vice President, Global Clinical Development, Medco Research Inc. and the Radiopharmaceutical Division of Du Pont Merck Pharmaceutical Company, which is now Lantheus Medical Imaging.
Dr. Orlandi received his medical degree with honors from the University of Pavia Medical School, Pavia, Italy. He is currently an Adjunct Assistant Professor of Medicine at Tufts University School of Medicine, Boston. Additionally, Dr. Orlandi is a founding member of the American Society of Nuclear Cardiology (ASNC), a Fellow of the American College of Cardiology (ACC), European Society of Cardiology (ESC) and American College of Angiology (ACA). He is also a member of the ESC Industry Panel.
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The Company’s proven success in the field of diagnostic imaging provides a strong platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, TechneLite® (Technetium Tc99m Generator), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection). Lantheus has approximately 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that may be described from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.